Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Travere Therapeutics Inc
(NQ:
TVTX
)
13.48
+0.88 (+6.98%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 13, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Travere Therapeutics Inc
< Previous
1
2
3
4
5
6
7
Next >
Stocks That Hit 52-Week Lows On Monday
December 12, 2022
Monday saw 196 companies set new 52-week lows.
Via
Benzinga
4 Analysts Have This to Say About Travere Therapeutics
December 05, 2022
Via
Benzinga
Where Travere Therapeutics Stands With Analysts
December 05, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
November 22, 2022
During Tuesday's trading, 160 companies set new 52-week lows.
Via
Benzinga
Recap: Travere Therapeutics Q3 Earnings
October 27, 2022
Travere Therapeutics (NASDAQ:TVTX) reported its Q3 earnings results on Thursday, October 27, 2022 at 04:01 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Analyst Cuts Price On Travere Therapeutics Citing Expected Delayed PDUFA
October 14, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 5, 2022
December 05, 2022
Via
Benzinga
Travere Therapeutics Earnings Perspective: Return On Capital Employed
November 03, 2022
Benzinga Pro data, Travere Therapeutics (NASDAQ:TVTX) reported Q3 sales of $53.50 million. Earnings fell to a loss of $69.66 million, resulting in a 3.91% decrease from last quarter.
Via
Benzinga
Expert Ratings for Travere Therapeutics
October 14, 2022
Within the last quarter, Travere Therapeutics (NASDAQ:TVTX) has observed the following analyst ratings:
Via
Benzinga
FDA Requests For Additional Monitoring For Travere Therapeutics' Sparsentan In Rare Kidney Disease
October 14, 2022
Via
Benzinga
Travere Therapeutics Return On Capital Employed Overview
August 15, 2022
Via
Benzinga
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
November 01, 2022
October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the...
Via
Benzinga
Earnings Outlook For Travere Therapeutics
October 26, 2022
Travere Therapeutics (NASDAQ:TVTX) is set to give its latest quarterly earnings report on Thursday, 2022-10-27. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Insider Buying 2022: 15 Stocks to Bet On Despite the Bear Market
October 05, 2022
Following insider buying is a savvy way for retail investors to profit even when a bear market is raging on Wall Street. Here are 15 stocks.
Via
InvestorPlace
Recap: Travere Therapeutics Q2 Earnings
August 04, 2022
Travere Therapeutics (NASDAQ:TVTX) reported its Q2 earnings results on Thursday, August 4, 2022. Here's what investors need to know about the announcement.
Via
Benzinga
Where Travere Therapeutics Stands With Analysts
July 26, 2022
Travere Therapeutics (NASDAQ:TVTX) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Analyst Ratings for Travere Therapeutics
May 17, 2022
Within the last quarter, Travere Therapeutics (NASDAQ:TVTX) has observed the following analyst ratings:
Via
Benzinga
Earnings Scheduled For October 27, 2022
October 27, 2022
Companies Reporting Before The Bell • Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million.
Via
Benzinga
Travere Therapeutics Pops After Snagging Priority Review For A New Kidney Drug
May 16, 2022
The FDA will review Travere's drug by mid-November for a kidney disease.
Via
Investor's Business Daily
121 Stocks That Hit Their 52-Week Low
October 14, 2022
New Equities that Broke Through 52-Week Lows Friday Morning During Friday's morning session, 121 stocks hit new 52-week lows.
Via
Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
August 22, 2022
Via
Benzinga
Travere, CSL's Sparsentan Application Is Under European Review For Rare Kidney Disorder
August 22, 2022
Via
Benzinga
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
August 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
FDA Says Travere's Sparsentan Data Not Sufficient For Accelerated Approval In One Indication
August 04, 2022
Travere Therapeutics Inc (NASDAQ: TVTX) completed its planned FDA Type A meeting for a potential submission for accelerated approval of sparsentan for focal segmental glomerulosclerosis (FSGS), a rare...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
August 03, 2022
Gainers
Via
Benzinga
4 Analysts Have This to Say About Travere Therapeutics
July 26, 2022
Over the past 3 months, 4 analysts have published their opinion on Travere Therapeutics (NASDAQ:TVTX) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
June 17, 2022
Gainers Travere Therapeutics (NASDAQ:TVTX) stock increased by 16.5% to $28.87 during Friday's after-market session. The market value of their outstanding shares is at $1.8 billion.
Via
Benzinga
HC Wainwright & Co. Maintains Buy Rating for Travere Therapeutics: Here's What You Need To Know
May 17, 2022
HC Wainwright & Co. has decided to maintain its Buy rating of Travere Therapeutics (NASDAQ:TVTX) and raise its price target from $45.00 to $46.00. Shares of Travere Therapeutics are trading up 8.5%...
Via
Benzinga
FDA Accepts Travere Therapeutics' NDA for Sparsentan with Priority Review
May 16, 2022
The U.S. Food and Drug Administration (FDA) has accepted Travere Therapeutics’ (NASDAQ: TVTX) New Drug Application (NDA) under Subpart H and granted Priority Review of sparsentan for the treatment of...
Via
Benzinga
Here's Why Travere Therapeutics Shares Are Rising Today
May 16, 2022
Travere Therapeutics Inc (NASDAQ: TVTX) shares are trading higher by 7.66% at $23.88 after the company received a priority review from the FDA for its treatment of IgA Nephropathy...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.